agapeatpgroup.com (ATPC) - Long-Term Debt to Capital Coefficient

Agape ATP - graphic logo of issuer ATPC

Agape ATP Corporation (ATPC) relies on a network of Asian wellness centers and direct product sales, which is corroborated by the long-term debt financial leverage ratio. The 0.00 level indicates the status of the parameter as the company establishes barriers to entry for competitors through its ecosystem of clinics and regulatory standards. Simultaneously, the business is developing IT services for predictive metabolism analysis, integrating digital transformation into preventive medicine.

agapeatpgroup.com (ATPC): Long-Term Debt to Equity from 02/21/2024 to 10/31/2026
Signature product of Agape ATP Corp

This ratio measures the proportion of debt with a maturity exceeding one year relative to equity. It allows an investor to assess financial stability and the extent of the business's dependence on external financing. The trend of the long-term debt-to-equity ratio reflects the balance between bankruptcy risks and expansion rates. For Agape ATP Corporation (ATPC), this indicator is critical during the transition from capital-intensive clinics to scalable e-commerce. A reduction in the debt load would confirm the effectiveness of the digital transformation and the optimization of operating expenses.

Analysis of competing companies

Ascendis Pharma AS - Long-Term Liabilities to Equity|Long-Term Debt to Capital MDGL|CORT (Corcept Therapeutics Corp) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital RYTM (Rhythm Pharmaceuticals)|Long-Term Debt to Capital akerotx.com AKRO|MTSR - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient MLTX (MoonLake Immunotherapeutics AG)|Crinetics Pharma (CRNX) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio NewAmsterdam Pharma Corp|SLNO (Soleno Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital amicusrx.com|Long-Term Debt to Equity Ratio ETNB (89bio)|AGIO (Agios) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Structure Pharma GPCR|MDXG - Long-Term Debt to Equity Ratio|Rezolute, Inc. - Long-Term Debt to Capital|Long-Term Liabilities to Capital lexpharma.com|MBX (MBX Biosciences) - Long-Term Debt to Equity Ratio|ALT: Long-Term Loans to Capital Ratio|AARD (Aardvark Therapeutics Corp) - Long-Term Debt to Capital|Long-Term Debt to Capital Sagimet Biosciences Inc|Long-Term Debt to Capital BIOA|Long-Term Debt to Equity BMEA (biomeafusion.com)|Long-Term Debt to Equity Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. (GUTS) - Long-Term Liabilities to Capital|VTVT - Long-Term Debt to Equity|PLUR: Long-Term Debt to Equity|SYBX: Long-Term Debt to Capital|LPCN - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Matinas BioPharma Holdings, Inc.|Spruce Biosciences Inc. (SPRB) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Galecto Corp (GLTO)|Long-Term Debt to Equity Ratio Carmell Therapeutics CTCX|Long-Term Debt to Capital LUMO (Lumos Pharma, Inc.)|Long-Term Debt to Capital organovo.com ONVO|Radius Recycling - Long-Term Debt to Capital